# Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir

> **NCT03309566** · PHASE4 · COMPLETED · sponsor: **Laboratorio Elea Phoenix S.A.** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Efavirenz, tenofovir disoproxil fumarate and emtricitabine

## Key facts

- **NCT ID:** NCT03309566
- **Lead sponsor:** Laboratorio Elea Phoenix S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-04
- **Primary completion:** 2017-02-28
- **Final completion:** 2017-02-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03309566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03309566, "Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03309566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*